Vivos in The News Explore The Stories LeadershipFinancial Results & SEC FilingsStock PricingGovernanceNews + Events Menu LeadershipFinancial Results & SEC FilingsStock PricingGovernanceNews + Events Watch the 2024 Annual Stockholders Meeting Vivos Therapeutics Reports Third Quarter 2024 Financial Results and Provides Operational Update Vivos Therapeutics Schedules Release of Third Quarter 2024 Financial Results and Conference Call Vivos Therapeutics Secures FDA Clearance for Pediatric OSA Device, secures new AMA CPT Codes Vivos Therapeutics Granted CPT® Coverage and Reimbursement Codes for All Vivos CARE Oral Medical Devices From American Medical Association Vivos Therapeutics Announces Pricing of $4.3 Million Registered Direct Offering of Common Stock Priced At-The Market Under Nasdaq Rules Vivos Therapeutics Receives Groundbreaking FDA 510(k) Clearance to Treat Moderate to Severe Pediatric Sleep Apnea & Snoring Vivos Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update Vivos Therapeutics Schedules Release of Second Quarter 2024 Financial Results and Conference Call Vivos Therapeutics Announces Positive Results From 7-Month Multi-Site Pilot of its New Provider-Based Marketing and Distribution Model Load More
Vivos Therapeutics Granted CPT® Coverage and Reimbursement Codes for All Vivos CARE Oral Medical Devices From American Medical Association
Vivos Therapeutics Announces Pricing of $4.3 Million Registered Direct Offering of Common Stock Priced At-The Market Under Nasdaq Rules
Vivos Therapeutics Receives Groundbreaking FDA 510(k) Clearance to Treat Moderate to Severe Pediatric Sleep Apnea & Snoring
Vivos Therapeutics Announces Positive Results From 7-Month Multi-Site Pilot of its New Provider-Based Marketing and Distribution Model
